DBV, MacroGenics price follow-ons
DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) and MacroGenics Inc. (NASDAQ:MGNX) raised a combined $375.2 million in follow-on offerings.
DBV raised $244.8 million through the sale of 7.2 million ADSs at $34 in an offering underwritten by Citigroup; Morgan Stanley; Barclays; Leerink; and H.C. Wainwright. Each ADS represents one-half of an ordinary share. DBV proposed the offering on July 2, when its shares closed at $30.51. DBV gained $3.14 to $41.51 on NASDAQ on Wednesday, and rose EUR 6.74 (10%) to EUR 75.08 on Euronext. The company expects to begin a Phase III trial in 4Q15 of Viaskin Peanut in children aged 4-11; the therapy comprising peanut proteins delivered epicutaneously by Viaskin patch technology has breakthrough therapy and Fast Track designations from FDA to treat peanut allergy. ...